Stepan (SCL) Could Be 18% Below Fair Value After Strong Q3 Results And Dividend Hike

Analysts set a $85.0 price target for Stepan, expecting 2029 revenues of $2.8B, earnings of $305.5M, and a PE ratio of 8.1x with an 8.1% discount rate. The company reported strong Q3 results and raised its dividend.

Original reporting
Published Oct 30, 2026, 8:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 8:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Stepan (SCL) Could Be 18% Below Fair Value After Strong Q3 Results And Dividend Hike — source image
Decision brief

The 30-second read

$SCLBullishLow
01

Why it matters

The new consensus target could influence short‑term trading and analyst coverage.

02

Market read

Analyst target update provides modest new information for traders.

03

What to watch

Potential cost pressures and competitive dynamics not reflected in the target.

Relevance 4/10Novelty 4/10Timing: pre‑market today

Background

Stepan is a specialty chemicals producer listed on NYSE under SCL.

Company-level read

Ticker impact

$SCLBullishMedium confidence
Context

Analysts set a consensus price target of $85.0 for Stepan based on projected 2029 earnings and revenue.

Expected impact

likely upward pressure as the market prices in the higher target.

Evidence & confidence

The target reflects optimistic long‑term earnings growth, which may attract buyers.

Market effects

May lift sentiment for specialty chemicals peers.

Limited to US specialty chemicals sector.

Minimal.

Counterpoint

Target may be overly optimistic given macro uncertainties.

Key entities

  • Stepan Company

    US‑listed specialty chemicals manufacturer.

Related articles

$SCLMed

Stepan Co (SCL) (Q3 2026) Earnings Call Highlights: 7% Organic Volume Growth

Stepan Co (SCL) reported Q3 2026 earnings with 7% organic volume growth and 18% year-over-year adjusted EBITDA increase to $66.3M. Project Catalyst savings exceeded targets, and net leverage improved. Dividends increased for the 59th consecutive year. Challenges include weak polymer volumes in Europe and Asia, rising raw material costs, and a regulatory maintenance turnaround in Germany.

$SCLHighAI 8/10

Stepan (SCL) Q3 2026 Earnings Call Transcript

Stepan (SCL) reported Q3 2026 earnings with adjusted EBITDA up 18% YoY to $66.3M, driven by volume growth and margin recovery. Net income rose 64% to $17.8M. Sales increased across surfactants, polymers, and specialty products. Project Catalyst savings exceeded expectations. Management cited geopolitical risks and rising raw material costs as challenges.

$SCLMedAI 8/10

Stepan Company Q3 2026 Earnings Call Summary

Stepan Company reported Q3 2026 earnings with 7% organic volume growth, driven by North American polymers and surfactants. Margin recovery was sustained through pricing actions and cost offsets. Project Catalyst savings reached $23M quarterly, with expectations to exceed $25M in 2027. The company anticipates full-year 2026 adjusted EBITDA growth, positive free cash flow, and balance sheet deleveraging. Net leverage improved to 2.4x from 2.7x year-over-year.

$SCLMed

Stepan Q3 Earnings Call Highlights

Stepan Company (NYSE: SCL) reported Q3 net sales up 12% to $27M, with adjusted EBITDA rising 5% to $11.7M. Management cited higher volume in MCT products and cost pressures from volatile oil markets. Project Catalyst savings exceeded expectations, with $23M quarterly savings and $66M-$70M expected for 2026. Net debt reduced to $536M, and the dividend was raised by 2.5%.

$SCLMedAI 8/10

Stepan Q3 2026 slides: EPS doubles on volume growth, restructuring

Stepan Company (SCL) reported Q3 2026 adjusted EPS of $0.94, up 98% YoY, driven by 7% volume growth and restructuring savings. Revenue and EPS beat estimates. Shares rose 2.42%. Adjusted EBITDA increased 18% to $66.3M. Project Catalyst restructuring is ahead of schedule, with $23M quarterly savings. Net leverage ratio improved to 2.4x. Free cash flow was $8M, impacted by working capital build.